ArticleMolecular oncology2009
Full sequencing of TP53 identifies identical mutations within in situ and invasive components in breast cancer suggesting clonal evolution.
Article in Molecular oncology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The association between phosphatase and tensin homolog hypermethylation and patients with breast cancer, a meta-analysis and literature review.Scientific reports · 2016Pooled it
- Racial Disparity in Ductal Carcinoma in Situ: Risk-Predictive and Actionable Biomarkers for Early Intervention.Cancers · 2026Review
- Elucidating cooperative genetic events in DCIS progression in mutantProceedings of the National Academy of Sciences of the United States of America · 2026Article
- Quantitative assessment of HER2 expression in invasive ductal carcinoma and co-existing DCIS.Breast cancer research and treatment · 2025Article
- Progression from ductal carcinoma in situ to invasive breast cancer: molecular features and clinical significance.Signal transduction and targeted therapy · 2024Review
- Pharmacological reactivation of p53 in the era of precision anticancer medicine.Nature reviews. Clinical oncology · 2024Review
- Analysis of Intrinsic Breast Cancer Subtypes: The Clinical Utility of Epigenetic Biomarkers andInternational journal of molecular sciences · 2022Article
- Is loss of p53 a driver of ductal carcinoma in situ progression?British journal of cancer · 2022Review
- Mouse-INtraDuctal (MIND): an in vivo model for studying the underlying mechanisms of DCIS malignancy.The Journal of pathology · 2022Article
- Comparable cancer-relevant mutation profiles in synchronous ductal carcinoma in situ and invasive breast cancer.Cancer reports (Hoboken, N.J.) · 2020Article
- Genomic profiling of metaplastic breast carcinomas reveals genetic heterogeneity and relationship to ductal carcinoma.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2018Article
- Breast ductal carcinoma in situ carry mutational driver events representative of invasive breast cancer.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2017Article
- TP53 Mutations in Breast and Ovarian Cancer.Cold Spring Harbor perspectives in medicine · 2017Review
- TP53 Mutational Analysis Enhances the Prognostic Accuracy of IHC4 and PAM50 Assays.Scientific reports · 2015Article
- Appraisal of the technologies and review of the genomic landscape of ductal carcinoma in situ of the breast.Breast cancer research : BCR · 2015Review
- Silencing of ETS1 reverses adriamycin resistance in MCF-7/ADR cells via downregulation of MDR1.Cancer cell international · 2014Article
- Functional characterization of the 19q12 amplicon in grade III breast cancers.Breast cancer research : BCR · 2012Article
- The stemness phenotype model.ISRN oncology · 2012Article
- Frequent aberrant DNA methylation of ABCB1, FOXC1, PPP2R2B and PTEN in ductal carcinoma in situ and early invasive breast cancer.Breast cancer research : BCR · 2010Article
- Full sequencing of TP53 identifies identical mutations within in situ and invasive components in breast cancer suggesting clonal evolution.Molecular oncology · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In breast cancer, previous studies have suggested that somatic TP53 mutations are likely to be an early event. However, there are controversies regarding the cellular origin and linear course of breast cancer. The purpose of this study was to investigate tumor evolution in breast cancer by analyzing TP53 mutation status in tumors from various stages of the disease. The entire coding sequence of TP53 was sequenced in a cohort of pure ductal carcinoma in situ (DCIS), pure invasive cancer (≤15mm) and mixed lesions (i.e. invasive cancer with an in situ component). Of 118 tumor samples, 19 were found to harbor a TP53 mutation; 5 (15.6%) of the pure DCIS, 4 (10.5%) of the pure invasive cancers and 10 (20.8%) of the mixed lesions. In the mixed lesions, both the invasive and the DCIS components showed the same mutation in all 5 cases where the two components were successfully microdissected. Presence of the same mutation in both DCIS and invasive components from the same tumor indicates same cellular origin. The role of mutant TP53 in the progression of breast cancer is less clear and may vary between subtypes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.